Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249307 | 0.76 | MAPT (0.38) | NOTUMMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5004908 | 0.75 | NOTUM (0.44) | NOTUMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4379296 | 0.74 | POLB (0.43) | NOTUMKMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL5398794 | 0.72 | KMT2A (0.42) | NOTUMKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1149224 | 0.72 | TSHR (0.43) | KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1518200 | 0.72 | RAB9A (0.47) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30034979 | 0.72 | NOTUM (0.41) | NOTUMMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28275487 | 0.72 | KMT2A (0.36) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19500072 | 0.69 | KDM4E (0.41) | NOTUMKMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL21572924 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-7056944-B2 | Pyrazole compositions useful as inhibitors of erk | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-06 | — | — | US | disclosed |
| US-6994868-B2 | Compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| US-6849267-B2 | Compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-01 | — | — | US | disclosed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | disclosed |
| US-20040102506-A1 | Pyrazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED | 2004-05-27 | — | — | US | disclosed |
| US-20040048861-A1 | Compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-11 | — | — | US | disclosed |
| US-6699865-B2 | PROTEIN KINASE INHIBITORS, FOR TREATING CANCER INFLAMMATORY DISORDERS, RESTENOSIS, AND CARDIOVASCULAR DISEASE. | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-02 | — | — | US | disclosed |
| US-20030225151-A1 | Pyrazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-6593357-B1 | Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-15 | — | — | US | disclosed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | disclosed |
| US-20030049820-A1 | Compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-13 | — | — | US | disclosed |
| US-6528509-B1 | Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease | VERTEX PHARMACUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-20030040536-A1 | Pyrazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED | 2003-02-27 | — | — | US | disclosed |
| EP-1207864-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1200422-A2 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK | Vertex Pharmaceuticals Incorporated (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001057022-A2 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001056557-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040536-A1 | Pyrazole compositions useful as inhibitors of ERK | MAPK1, MAPK4, MAPK3 | NOTUM 4206/4885KMT2A 4112/4885HRH3 1866/4885 |
| US-20030049820-A1 | Compositions useful as inhibitors of ERK | GRPR, HSPD1, HSPA5 | NOTUM 4133/4885KMT2A 4769/4885HRH3 121/4885 |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, MAPK3, CDK1 | NOTUM 4276/4885KMT2A 1167/4885HRH3 815/4885 |
| US-20040048861-A1 | Compositions useful as inhibitors of ERK | GRPR, HSPD1, HSPA5 | NOTUM 4133/4885KMT2A 4769/4885HRH3 121/4885 |
| US-20040102506-A1 | Pyrazole compositions useful as inhibitors of ERK | MAPK1, MAPK4, MAPK3 | NOTUM 4206/4885KMT2A 4112/4885HRH3 1866/4885 |
| US-20030225151-A1 | Pyrazole compositions useful as inhibitors of ERK | MAPK1, MAPK4, MAPK3 | NOTUM 4206/4885KMT2A 4112/4885HRH3 1866/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | NOTUM 3906/4885KMT2A 1648/4885HRH3 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.